• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

The Global Market for Angiogenesis Therapeutic Products is Projected to Reach About US$ 22 Billion By 2012

Posted on: Saturday, 8 March 2008, 15:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c85209) has announced the addition of Angiogenesis Modulators to their offering.

This market insight report on Angiogenesis Modulators studies the impact of Inhibitors and Stimulators on various diseases. The study focuses on major angiogenesis inhibitors and their role in diseases such as cancer, dermatology, ophthalmology, rheumatology and other angiogenesis based diseases including endometriosis and inflammatory diseases. The emphasis is also given on major angiogenesis stimulators and their role in diseases such as cardiovascular disorders including ischemia, congestive heart failure, coronary artery disease, myocardial infarction and peripheral vascular disease and chronic wound care. The study provides global market analysis for angiogenesis therapeutic products by the above angiogenesis modulators and also by the disease areas such as cancer, cardiovascular disorders and other angiogenesis based diseases. The study includes estimates and projections for the total global angiogenesis therapeutic products market.

Global market for Angiogenesis therapeutic products is projected to reach about US$ 22 billion by 2012. Angiogenesis is the formation of new capillary blood vessels and plays an important role in several physiological processes such as wound repair, ovulation, embryonic development, and myocardium generation. With angiogenesis inhibitors showing great promise in reducing malignant tumors in rats, the market potential has greatly increased for therapeutic products in disease areas such as cancer, cardiovascular diseases, ophthalmic diseases, skin diseases, rheumatoid arthritis, and other angiogenesis based diseases.

Angiogenesis research has become one of the most interesting fields in biomedical areas. Cancer is the most prominent area for research with maximum number of drugs being targeted in this disease area. The tumors of cancer cannot survive without the existence and development of new blood vessels. This offers an important scope for researchers to restrict the cancer cells from expanding by restricting the formation of new blood vessels. Research on synthetic and natural angiogenesis inhibitors is also underway. The United States is the leading market for angiogenesis therapeutic products followed by Europe and Asia Pacific. Asia Pacific and Latin American markets are emerging markets with leading pharmaceutical companies outsourcing drug development and clinical trials in these developing regions.

Countries Covered:

United States

Europe

Germany

United Kingdom

France

Switzerland

Rest of Europe

Asia-Pacific

Japan

Rest of Asia-Pacific

Latin America

Rest of World

Companies Mentioned:

Abbott Laboratories (USA)

Adnexus Therapeutics, Inc. (USA)

Aeterna Zentaris, Inc. (Canada)

Alcon, Inc. (USA)

Amgen, Inc. (USA)

Angiotech Pharmaceuticals, Inc. (Canada)

Angstrom Pharmaceuticals, Inc. (USA)

Antisoma plc (UK)

Astrazeneca plc (UK)

Bayer Healthcare AG (Germany)

Callisto Pharmaceuticals, Inc. (USA)

Cardium Therapeutics, Inc. (USA)

Celgene Corporation (USA)

Chugai Pharmaceutical Co., Ltd. (Japan)

Collagenex Pharmaceuticals, Inc. (USA)

Eisai, Inc. (USA)

Entremed, Inc. (USA)

F.Hoffmann-La Roche Ltd. (Switzerland)

Genaera Corporation (USA)

Genentech, Inc. (USA)

Genvec, Inc. (USA)

Genzyme Corporation (USA)

Human Genome Sciences, Inc. (USA)

Imclone Systems, Inc. (USA)

Intradigm Corporation (USA)

Merck & Co., Inc. (USA)

Merck KGaA (Germany)

Novartis AG (Switzerland)

OSI Pharmaceuticals, Inc. (USA)

Oxigene, Inc. (USA)

Pfizer, Inc. (USA)

Progen Industries Ltd. (Australia)

TAP Pharmaceutical Products, Inc. (USA)

UCB SA (Belgium)

For more information visit http://www.researchandmarkets.com/reports/c85209.

Source: Business Wire

More News in this Category